Tethering: Fragment-based drug discovery

Annual Review of Biophysics and Biomolecular Structure

Volumn 33, Issue , 2004, Pages 199-223

  Erlanson, Daniel A ^a   Wells, James A ^a   Braisted, Andrew C ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

Disulfide exchange; Fragment assembly; Molecular recognition; Small molecule inhibitors; Structure based drug design

Indexed keywords

BASILIXIMAB; CASPASE; CASPASE INHIBITOR; DACLIZUMAB; INTERLEUKIN 2; N TOSYLPROLINE; PHOSPHOTYROSINE; PROLINE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; TETRAPEPTIDE; THIOL DERIVATIVE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

BINDING AFFINITY; BINDING SITE; DISULFIDE BOND; DRUG DETERMINATION; DRUG RESEARCH; DRUG TARGETING; MASS SPECTROMETRY; MOLECULAR RECOGNITION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; TECHNIQUE; TETHERING METHOD; X RAY CRYSTALLOGRAPHY;

BINDING SITES; DRUG DESIGN; PEPTIDE FRAGMENTS; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEINS;

EID: 2542542373     PISSN: 10568700     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.biophys.33.110502.140409     Document Type: Review

References (81)

1. Deleted in proof
2. Allen DA, Pham P, Choong IC, Fahr B, Burdett MT, et al. 2003. Identification of potent and novel small-molecule inhibitors of caspase-3. Bioorg. Med. Chem. Lett. 13:3651-55
3. Andersen HS, Olsen OH, Iversen LF, Sorensen AL, Mortensen SB, et al. 2002. Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of Protein Tyrosine Phosphatase 1B. J. Med. Chem. 45:4443-59
4. Arabaci G, Xiao-Chuan G, Beebe KD, Coggeshall KM, Pei D. 1999. α-haloacetophenone derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. J. Am. Chem. Soc. 121:5085-86
5. Arkin MR, Randal M, DeLano WL, Hyde J, Luong TN, et al. 2003. Binding of small molecules to an adaptive protein-protein interface. Proc. Natl. Acad. Sci. USA 100:1603-8
6. Barrett WC, DeGnore JP, Konig S, Fales HM, Keng Y-F, et al. 1999. Regulation of PTP1B via glutathionylation of the active site cysteine 215. Biochemistry 38:6699-705
7. Blundell TL, Jhoti H, Abell C. 2002. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1:45-54
8. Boehm HJ, Boehringer M, Bur D, Gmuender H, Huber W, et al. 2000. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 43:2664-74
9. Bohacek RS, McMartin C, Guida WC. 1996. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16:3-50
10. Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, et al. 2003. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc. 125:3714-15
11. Deleted in proof
12. Burke TR Jr, Yao ZJ, Liu DG, Voigt J, Gao Y. 2001. Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Biopolymers 60:32-44
13. Choong IC, Lew W, Lee D, Pham P, Burdett MT, et al. 2002. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J. Med. Chem. 45:5005-22
14. Cochran AG. 2001. Protein-protein interfaces: mimics and inhibitors. Curr. Opin. Chem. Biol. 5:654-59
15. Cochran AG, Tong RT, Starovasnik MA, Park EJ, McDowell RS, et al. 2001. A minimal peptide scaffold for beta-turn display: optimizing a strand position in disulfide-cyclized beta-hairpins. J. Am. Chem. Soc. 123:625-32
16. Costi MP, Tondi D, Rinaldi M, Barlocco D, Pecorari P, et al. 2002. Structure-based studies on species-specific inhibition of thymidylate synthase. Biochim. Biophys. Acta. 1587:206-14
17. DeLano WL. 2003. PyMOL molecular graphics system on the World Wide Web. http://pymol.sourceforge.net/
18. DeLano WL. 2002. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol. 12:14-20
19. Dolle RE, Hoyer D, Prasad CVC, Schmidt SJ, Helaszek CT, et al. 1994. P1 aspartate-based peptide α-((2,6-dichlorobenzoyl)oxy)methyl ketones as potent time-dependent inhibitors of interleukin-1b converting enzyme. J. Med. Chem. 37:563-64
20. Erlanson DA, Braisted AC, Raphael DR, Randal M, Stroud RM, et al. 2000. Site-directed ligand discovery. Proc. Natl. Acad. Sci. USA 97:9367-72
21. Erlanson DA, Lam JW, Wiesmann C, Luong TN, Simmons RL, et al. 2003. In situ assembly of enzyme inhibitors using extended tethering. Nat. Biotechnol. 21:308-14
22. Erlanson DA, McDowell RS, He MM, Randal M, Simmons RL, et al. 2003. Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. J. Am. Chem. Soc. 125:5602-3
23. Fejzo J, Lepre C, Xie X. 2003. Application of NMR screening in drug discovery. Curr. Top. Med. Chem. 3:81-97
24. Fejzo J, Lepre CA, Peng JW, Bemis GW, Ajay, et al. 1999. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem. Biol. 6:755-69
25. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, et al. 1998. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95:12022-27
26. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson D, Thomberry NA. 1998. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273:32608-13
27. Gilbert HF. 1995. Thiol/disulfide exchange equilibria and disulfide bond stability. Methods Enzymol. 251:8-28
28. Graczyk PP. 1999. Caspase inhibitors - a chemist's perspective. Restor. Neurol. Neurosci. 14:1-23
29. Ham SW, Park J, Lee SJ, Yoo JS. 1999. Selective inactivation of protein tyrosine phosphatase PTP1B by sulfone analogue of naphthoquinone. Bioorg. Med. Chem. Lett. 9:185-86
30. Han MS, Ryu CH, Chung SJ, Kim DH. 2000. A novel strategy for designing irreversible inhibitors of metalloproteases: acetals as latent electrophiles that interact with catalytic nucleophile at the active site. Org. Lett. 2:3149-52
31. Hernandez AA, Roush WR. 2002. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr. Opin. Chem. Biol. 6:459-65
32. Houk J, Whitesides GM. 1987. Structure-reactivity relations for thiol-disulfide interchange. J. Am. Chem. Soc. 109:6825-36
33. Huc I, Lehn JM. 1997. Virtual combinatorial libraries: dynamic generation of molecular and supramolecular diversity by self-assembly. Proc. Natl. Acad. Sci. USA 94:2106-10
34. Huse M, Kuriyan J. 2002. The conformational plasticity of protein kinases. Cell 109:275-82
35. Hyatt DC, Maley F, Montfort WR. 1997. Use of strain in a stereospecific catalytic mechanism: crystal structures of Escherichia coli thymidylate synthase bound to FdUMP and methylenetetrahydrofolate. Biochemistry 36:4585-94
36. Hyde J, Braisted AC, Randal M, Arkin MR. 2003. Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2. Biochemistry 42:6475-83
37. Jacoby E, Davies J, Blommers MJ. 2003. Design of small molecule libraries for NMR screening and other applications in drug discovery. Curr. Top. Med. Chem. 3:11-23
38. Jahnke W, Florsheimer A, Blommers MJ, Paris CG, Heim J, et al. 2003. Second-site NMR screening and linker design. Curr. Top. Med. Chem. 3:69-80
39. Jencks WP. 1981. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. USA 78:4046-50
40. Johnson TO, Ermolieff J, Jirousek MR. 2002. Protein Tyrosine Phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug. Discov. 1:696-709
41. Kamb A, Finer-Moore J, Calvert AH, Stroud RM. 1992. Structural basis for recognition of polyglutamyl folates by thymidylate synthase. Biochemistry 31:9883-90
42. Kaur S, McGuire L, Tang D, Dollinger G, Huebner V. 1997. Affinity selection and mass spectrometry-based strategies to identify lead compounds in combinatorial libraries. J. Protein Chem. 16:505-11
43. Keire DA, Strauss E, Guo W, Noszál B, Rabenstein DL. 1992. Kinetics and equilibria of thiol/disulfide interchange reactions of selected biological thiols and related molecules with oxidized glutathione. J. Org. Chem. 57:123-27
44. Lehn JM, Eliseev A. 2001. Dynamic combinatorial chemistry. Science 291:2331-32
45. Lesuisse D, Lange G, Deprez P, Benard D, Schoot B, et al. 2002. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of SRC SH2. J. Med. Chem. 45:2379-87
46. Liu G, Szczepankiewicz BG, Pei Z, Janowick DA, Xin Z, et al. 2003. Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of Protein Tyrosine Phosphatase 1B. J. Med. Chem. 46:2093-103
47. Margolin N, Raybuck SA, Wilson K, Chen W, Fox T, et al. 1997. Substrate and inhibitor specificity of interleukin-1β-converting enzyme and related caspases. J. Biol. Chem. 272:7223-28
48. Marsham PR, Wardleworth JM, Boyle FT, Hennequin LF, Kimbell R, et al. 1999. Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors. J. Med. Chem. 42:3809-20
49. McBride CB, McPhail LT, Steeves JD. 1999. Emerging therapeutic targets in caspase-dependent disease. Expert Opin. Ther. Targets 3:391-411
50. McGovern SL, Caselli E, Grigorieff N, Shoichet BK. 2002. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45:1712-22
51. Myers JK, Widlanski TS. 1993. Mechanism-based inactivation of prostatic acid phosphatase. Science 262:1451-53
52. Nakamura CE, Abeles RH. 1985. Mode of interaction of beta-hydroxy-beta- methylglutaryl coenzyme A reductase with strong binding inhibitors: compactin and related compounds. Biochemistry 24:1364-76
53. Nelson BH, Willerford DM. 1998. Biology of the interleukin-2 receptor. Adv. Immunol. 70:1-81
54. Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, Greer J. 2000. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 18:1105-8
55. Niimi T, Orita-Igarashi M, Okazawa M, Sakashita H, Kikuchi K, et al. 2001. Design and synthesis of non-peptidic inhibitors for the syk C-terminal SH2 domain based on structure-based in-silico screening. J. Med. Chem. 44:4737-40
56. Obita T, Muto T, Endo T, Kohda D. 2003. Peptide library approach with a disulfide tether to refine the Tom20 recognition motif in mitochondrial presequences. J. Mol. Biol. 328:495-504
57. O'Shea EK, Rutkowski R, Stafford WF III, Kim PS. 1989. Preferential heterodimer formation by isolated leucine zippers from fos and jun. Science 245:646-48
58. Otto HH, Schirmeister T. 1997. Cysteine proteases and their inhibitors. Chem. Rev. 97:133-72
59. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, et al. 2002. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9:268-72
60. Powers JC, Asgian JL, Ekici OD, James KE. 2002. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102:4639-750
61. Ramstrom O, Lehn JM. 2002. Drug discovery by dynamic combinatorial libraries. Nat. Rev. Drug Discov. 1:26-32
62. Rishton GM. 2003. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov. Today 8:86-96
63. Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D. 2000. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by Protein Tyrosine Phosphatase 1B. Mol. Cell 6:1401-12
64. Salto R, Babe LM, Li J, Rose JR, Yu Z, et al. 1994. In vitro characterization of nonpeptide irreversible inhibitors of HIV proteases. J. Biol. Chem. 269:10691-98
65. Sarmiento M, Puius YA, Vetter SW, Keng YF, Wu L, et al. 2000. Structural basis of plasticity in Protein Tyrosine Phosphatase 1B substrate recognition. Biochemistry 39:8171-79
66. Sauve K, Nachman M, Spence C, Bailon P, Campbell E, et al. 1991. Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 88:4636-40
67. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-42
68. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531-34
69. Stanojevic D, Verdine GL. 1995. Deconstruction of GCN4/GCRE into a monomeric peptide-DNA complex. Nat. Struct. Biol. 2:450-57
70. Stout TJ, Sage CR, Stroud RM. 1998. The additivity of substrate fragments in enzyme-ligand binding. Structure 6:839-48
71. Swayze EE, Jefferson EA, Sannes-Lowery KA, Blyn LB, Risen LM, et al. 2002. SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. J. Med. Chem. 45:3816-19
72. Thanos CD, Randal M, Wells JA. 2003. Potent small-molecule binding to a dynamic hot spot on IL-2. J. Am. Chem. Soc. 125:15280-81
73. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, et al. 1997. A combinatorial approach defines specificities of members of the caspase family and granzyme B. J. Biol. Chem. 272:17907-11
74. Tilley JW, Chen L, Fry DC, Emerson SD, Powers GD, et al. 1997. Identification of a small molecule inhibitor of the IL-2/IL-2Rα receptor interaction which binds to IL-2. J. Am. Chem. Soc. 119:7589-90
75. Toogood PL. 2002. Inhibition of protein-protein association by small molecules: approaches and progress. J. Med. Chem. 45:1543-58
76. Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, et al. 2001. 6-substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 44:2719-34
77. van Dongen M, Weigelt J, Uppenberg J, Schultz J, Wikstrom M. 2002. Structure-based screening and design in drug discovery. Drug Discov. Today 7:471-78
78. van Dongen MJ, Uppenberg J, Svensson S, Lundback T, Akerud T, et al. 2002. Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation. J. Am. Chem. Soc. 124:11874-80
79. Yue T-L, Ohlstein E, Ruffolo R. 1999. Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases. Curr. Opin. Chem. Biol. 3:474-80
80. Zhang ZY. 2002. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol. 42:209-34
81. Zurawski SM, Vega F Jr, Doyle EL, Huyghe B, Flaherty K, et al. 1993. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor. EMBO J. 12:5113-19